Human CellExp™ B7-H6, human recombinant
Natural cytotoxicity triggering receptor 3 ligand 1
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q68D85 |
---|---|
Calculated MW | 80 kDa |
Gene ID | 374383 |
---|---|
Other Names | B7-H6, Natural cytotoxicity triggering receptor 3 ligand 1, B7H6, B7 homolog 6, NCR3LG1 |
Gene Source | Human |
Source | HEK 293 cells |
Assay&Purity | SDS-PAGE;≥ 98% |
Recombinant | Yes |
Target/Specificity | NCR3LG1 |
Application Notes | Reconstitute in 1X PBS to the desired protein concentration. |
Format | Lyophilized |
Storage | -20°C; Lyophilized from 0.2 µm-filtered solution in PBS. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
B7-H6 is a glycosylated member of the B7 family of immune costimulatory proteins. Orthologs in mouse and rat have not been identified. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells. It does not show binding to NKp44, NKp46, or NKG2D. Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytolysis. B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors. The expression of NKp30 ligands on tumor cells correlates with tumor cell sensitivity to NKp30-dependent cell lysis.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.